Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Drug

Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study

Fineline Cube May 14, 2020

Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...

Company Deals

Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico

Fineline Cube May 14, 2020

Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...

Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Policy / Regulatory

Enhancing Clinical Trial Success: CDE’s New Adaptive Design Framework Opens for Comment

Fineline Cube May 14, 2020

The newly proposed guidelines are designed to be applicable across a spectrum of confirmatory clinical...

Company

Thermo Fisher Scientific Develops Serology Test to Detect COVID-19 Antibodies in Collaboration with WuXi Diagnostics and Mayo Clinic

Fineline Cube May 14, 2020

Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...

Company

Cuban-Chinese Pharma Synergy: Joint R&D and Sales Initiative Targets USD 24.53 Billion in Sales

Fineline Cube May 14, 2020

In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered...

Deals

Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal

Fineline Cube May 14, 2020

Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody

Fineline Cube Nov 4, 2019

China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...

Company

LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development

Fineline Cube Jan 28, 2019

LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...

Hospital

China’s Ministry of Health Tightens Organ Transplant Regulations with Expert Conference

Fineline Cube Apr 4, 2007

Shi Bingyi, a distinguished Member of the National Committee of the CPPCC (Chinese People’s Political...

R&D

China Launches Unprecedented Multi-Center Hypertension Study with Global Implications

Fineline Cube Apr 4, 2007

On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced...

Company

China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments

Fineline Cube Apr 4, 2007

China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a...

Policy / Regulatory

Shanghai to Launch China’s Largest ADR Database, Enhancing Pharmaceutical Oversight

Fineline Cube Apr 4, 2007

Shanghai is advancing towards a significant milestone in pharmaceutical safety with plans to establish the...

Policy / Regulatory

China Unveils TCM Development Guidelines: A Strategic Defense of Traditional Medicine

Fineline Cube Apr 4, 2007

In a strategic move to assert the value and historical significance of Traditional Chinese Medicine...

Company

India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers

Fineline Cube Apr 4, 2007

In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against...

Company

Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006

Fineline Cube Apr 4, 2007

Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...

Hospital R&D

Ruijin Hospital Researchers Uncover Five New Mutations in Rare 17OHD Endocrine Disorder

Fineline Cube Apr 4, 2007

In a significant advancement in endocrine research, scientists within the Endocrine Department at Ruijin Hospital...

Policy / Regulatory

China’s SFDA Mandates Official Position Rotation to Boost Transparency

Fineline Cube Apr 4, 2007

China’s State Food and Drug Administration (SFDA) is poised to embrace a new era of...

Policy / Regulatory

Guangdong’s ‘Sunlight Purchase’ System Sparks Drug Pricing War and Uncovers Pricing Anomalies

Fineline Cube Apr 4, 2007

Since 2007, Guangdong province’s medical facilities have utilized an online procurement system known as “Sunlight...

Hospital R&D

Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study

Fineline Cube Apr 4, 2007

In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17...

Posts pagination

1 … 709 710 711

Recent updates

  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
  • Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Company

Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.